Stephens Is Bullish on Guardian Pharmacy Services, Inc. (GRDN) After 2026 Forecast Update

We recently compiled a list of the 12 Cheap Small-Cap Stocks to Invest In Before the Next Breakout. Guardian Pharmacy Services, Inc. is one of the best small-cap stocks to invest in.

TheFly reported on January 14 that Stephens analyst Raj Kumar maintained an Overweight rating on GRDN and raised the price target to $36 from $35. The update came after Guardian completed the acquisition of one long-term care pharmacy in Montana, released its 2026 forecast, and reaffirmed its 2025 revenue and adjusted EBITDA guidance.

Separately, a preliminary forecast for the fiscal year 2026 was also released on January 13 by Guardian Pharmacy Services, Inc. (NYSE:GRDN), which estimated revenue between $1.40 billion and $1.42 billion after accounting for recent reductions in wholesale acquisition costs (WAC) and adjustments to drug prices under the Inflation Reduction Act. The business anticipates strong single-digit revenue growth, excluding these effects. A year-over-year rise of roughly 11% and an improvement in the adjusted EBITDA margin of over 8% are reflected in the predicted adjusted EBITDA of $115 million to $118 million.

Guardian Pharmacy Services, Inc. (NYSE:GRDN) is a U.S. long‑term care (LTC) pharmacy services company that provides technology‑enabled medication management and pharmacy support to residents of assisted living, behavioral health, and skilled nursing facilities.

While we acknowledge the potential of GRDN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.